Evidence map›Paper›PMID 42170236›Full record

ArticleMaterials today. Bio2026

Mucoadhesive oral nanovaccine delivery system with immunomodulatory capacity for synergistic colorectal cancer therapy.

Qian Ming, Junjie Lin, Yingying Zhou, Ziqi Song, Zihan Yu, Xinze Liu, Xiao Sun, Lianyu Zhao, Changyu Lu, Natong Liu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Qian MingSchool of Life Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, 271016, China.
Junjie LinMedical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, China.
Yingying ZhouSchool of Life Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, 271016, China.
Ziqi SongMedical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, China.
Zihan YuMedical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, China.
Xinze LiuMedical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, China.
Xiao SunMedical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, China.
Lianyu ZhaoMedical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, China.
Changyu LuMedical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, China.
Natong LiuMedical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, China.
Yanan QinMedical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, China.
Jing WuDepartment of Pharmacy, Shandong University Affiliated Public Health Clinical Center, Jinan, 250100, China.
Zhaowei LiSchool of Radiology, Shandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, 271016, China.
Fengying ShaoSchool of Life Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, 271016, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) remains a prevalent malignancy, with current chemotherapies limited by drug resistance, poor bioavailability, and severe toxicity. Although cancer vaccines offer a promising alternative, their efficacy is constrained by inefficient tumor targeting and insufficient immune activation. Here, we present an oral nanovaccine delivery system (HML@HN) that integrates gastric protection, intestinal adhesion, tumor-specific delivery, and robust immune activation for enhanced CRC immunotherapy. The HML@HN nanovaccine is constructed by loading 5-FU-containing tumor cell lysate (TCL) into hollow manganese dioxide (HM) and co-coating with norepinephrine (NE) and hyaluronic acid (HA). The NE coating safeguards against gastric degradation while conferring mucoadhesive properties for prolonged intestinal retention, and HA enables active tumor targeting via CD44-mediated endocytosis. Upon internalization, the HM core responds to glutathione in the tumor microenvironment, triggering Mn

Indexed as

Colorectal cancer immunotherapyGastric protectionIntestinal adhesionOral nanovaccineTumor-specific delivery

Identifiers

PMID42170236
PMCPMC13188130

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.